Barclays Reiterates “Hold” Rating for Retrophin (NASDAQ:RTRX)

Retrophin (NASDAQ:RTRX)‘s stock had its “hold” rating reiterated by stock analysts at Barclays in a report issued on Friday, AnalystRatings.com reports. They presently have a $21.00 price objective on the biopharmaceutical company’s stock. Barclays‘s price target would suggest a potential upside of 5.63% from the company’s current price.

A number of other research analysts have also commented on RTRX. BMO Capital Markets lowered their price objective on shares of Retrophin from $34.00 to $31.00 in a research note on Monday, July 13th. BTIG Research initiated coverage on shares of Retrophin in a research note on Tuesday, June 16th. They set a “buy” rating and a $25.00 price objective on the stock. Zacks Investment Research upgraded shares of Retrophin from a “hold” rating to a “strong-buy” rating and set a $23.00 price target on the stock in a research report on Wednesday, July 15th. ValuEngine lowered shares of Retrophin from a “strong-buy” rating to a “buy” rating in a research report on Friday, April 17th. Finally, Canaccord Genuity restated a “buy” rating and issued a $26.00 price target on shares of Retrophin in a research report on Tuesday, May 19th. One investment analyst has rated the stock with a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $27.25.

Shares of RTRX traded down $0.81 during mid-day trading on Friday, reaching $19.88. 647,795 shares of the company’s stock traded hands, compared to its average volume of 438,665. The business’s 50-day moving average price is $19.03 and its 200-day moving average price is $16.31. The company has a debt-to-equity ratio of 0.92, a quick ratio of 5.88 and a current ratio of 5.97. Retrophin has a 12 month low of $8.98 and a 12 month high of $21.92.

Retrophin (NASDAQ:RTRX) last posted its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported ($0.58) EPS for the quarter, meeting the Zacks’ consensus estimate of ($0.58). Retrophin had a negative net margin of 49.13% and a negative return on equity of 39.84%. The business had revenue of $48.43 million for the quarter, compared to analyst estimates of $48.50 million. On average, analysts predict that Retrophin will post -1.56 earnings per share for the current year.

In other Retrophin news, Director Steve Aselage sold 10,000 shares of Retrophin stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $20.00, for a total transaction of $200,000.00. Following the transaction, the director now directly owns 238,732 shares in the company, valued at approximately $4,774,640. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Over the last quarter, insiders have sold 17,234 shares of company stock worth $316,677. Corporate insiders own 4.63% of the company’s stock.

Several large investors have recently modified their holdings of the business. Mackay Shields LLC boosted its stake in shares of Retrophin by 18.3% during the 2nd quarter. Mackay Shields LLC now owns 81,300 shares of the biopharmaceutical company’s stock valued at $1,659,000 after buying an additional 12,600 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of Retrophin by 256.4% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,734 shares of the biopharmaceutical company’s stock valued at $158,000 after buying an additional 5,564 shares during the period. SG Americas Securities LLC boosted its stake in shares of Retrophin by 28.9% during the 2nd quarter. SG Americas Securities LLC now owns 10,745 shares of the biopharmaceutical company’s stock valued at $219,000 after buying an additional 2,407 shares during the period. AXA boosted its stake in shares of Retrophin by 19.3% during the 1st quarter. AXA now owns 197,400 shares of the biopharmaceutical company’s stock valued at $2,880,000 after buying an additional 32,000 shares during the period. Finally, Invesco Ltd. boosted its stake in shares of Retrophin by 54.0% during the 1st quarter. Invesco Ltd. now owns 26,646 shares of the biopharmaceutical company’s stock valued at $389,000 after buying an additional 9,349 shares during the period.

About Retrophin

Retrophin, Inc, a biopharmaceutical company, focuses on the identification, development, acquisition, and commercialization of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola, a tiopronin tablet for the treatment of cystinuria.

Further Reading: What is diluted earnings per share (Diluted EPS)?

Analyst Recommendations for Retrophin (NASDAQ:RTRX)

Receive News & Ratings for Retrophin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin and related companies with MarketBeat.com's FREE daily email newsletter.